A Phase 2, Two Stage, Open-Label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-Inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Dexamethasone; Ruxolitinib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 20 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.